Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society Congress
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Angkor Resources' Subsidiary Implements Playgrounds For Rural Schools In Block VIII Drilling Area, Cambodia
Brixton Metals Drills 906 g/t Silver over 4.3 m, including 1,329 g/t Silver over 1.8 m, all within 23.7 m of 206.6 g/t Silver at its Langis Project And 4.95 m of 493 g/t silver, including 1,798 g/t silver over 1.0 m
Charbone Annonce l'Ajout de 22 Nouveaux Clients d'Helium au Quebec et Poursuit l'Expansion de sa Plateforme de Gaz Industriels
CHARBONE Announces the Addition of 22 New Helium Customers in Quebec and Continues the Expansion of its Industrial Gas Platform
